Absci Corp

Absci Corp (ABSI) priced its initial public offering on Jul 23, 2021 at $16.00 per share, within its $15.00–$17.00 range, raising $200M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $1.45B. J.P. Morgan was lead-left underwriter, joined by Credit Suisse, BofA Securities and TD Cowen and others. Goodwin Procter advised the company and Latham & Watkins advised the underwriters.

Absci Corp. operates an AI-powered Integrated Drug Creation Platform that unifies biologic drug discovery and cell line development. It combines synthetic biology and deep learning to design, screen and scale production of new biologic drug candidates with partners.

Status

IPO

Ticker

ABSI

Exchange

Nasdaq Global Market

Priced

Jul 23, 2021

IPO price

$16.00

Price range

$15.00–$17.00

Raised

$200M

Market cap at IPO price

$1.45B

First filed

Jun 30, 2021

Underwriters

J.P. Morgan, Credit Suisse, BofA Securities, TD Cowen and Stifel

Company counsel

Goodwin Procter

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

WA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.